AMM673-61 [Monoclonal Antibody]
BRAF Mouse Monoclonal Antibody
www.yhsbio.com
market@yhsbio.com
support@yhsbio.com
+86-21-54651191
Room 703,Building 6,333# Guiping
Rd.,Xuhui District,Shanghai,China
DATASHEET
Species:   Mouse
Applications:   WB IHC ELISA
Immunogen Range:   A purified recombinant fragment of human BRAF expressed in E. Coli
Clonality:   Monoclonal Antibody
Isotype:   IgG1
GENE ID:   673
Swiss Prot:   P15056
Synonyms:   B-RAF, B-RAF proto-oncogene serine/threonine-protein kinase, B-Raf proto-oncogene serine/threonine-protein kinase, BRAF, BRAF1, EC 2.7.1.37, EC 2.7.11.1, RAFB1, RMIL, RMIL serine/threonine-protein kinase, c-RMIL, kinase B-Raf, p94, v-Raf murine sarcoma vi
Purification:   Affinity chromatography
Storage:   Store at -20°C or -80°C in PBS with 0.02% sodium azide and 50% glycerol. Avoid freeze/thaw cycles.
Background:   B-Raf is a tyrosine kinase-like kinase of the RAF family. Involved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron. Frequently mutated in thyroid cancers, skin melanomas and at lower frequency in a wide range of human cancers. An activating mutation, mimicking phosphorylation of the activation loop, is seen in 60% of malignant melanoma samples. Raf mutations are generally exclusive to Ras activating mutations. Activating mutations are also seen in ~10% of colorectal cancers, in lung cancers and gliomas, and at a lower rate in several other tumors. Inactivating mutations are also seen and may result in activation of c-Raf and Erk. Mutations in B-Raf, MEK1 and MEK2 also associated with cardiofaciocutaneous syndrome, displaying morphological, cardiac and mental defects. Approved Inhibitor: Nexavar/Sorafenib.
Caculated MW:   84 kDa
Observed MW:   Refer to Figures
Applications:   WB 1:500-1:2000
IHC 1:200-1:1000
Reacitivity:   Human
For research use only. Not intended for diagnostic or therapeutic use!
Additional information